Sarah Flossdorf

Sarah Flossdorf

Auto-generated profile, based on publicly available information

Sarah Flossdorf

Institute for Medical Informatics, Biometry and Epidemiology University Hospital Essen Essen Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2025 in Blood
Verified
Journal Article
Open access
MMMaximilian Merz
Maximilian Merz
NGNico Gagelmann
Nico Gagelmann
SSSamih Smaili
Samih Smaili
SFSarah Flossdorf
Sarah Flossdorf
SSSandra Sauer
Sandra Sauer
Nicolaus KrögerNicolaus Kröger
Nicolaus Kröger
Cellular therapies targeting B-cell maturation antigen have shown promise in controlled clinical trials, but their impact in broader, diverse patient populations remains underexplored. This study examines the real-world efficacy and safety in 343 triple-class–exposed patients with relapsed and refractory multiple myeloma who received idecabtagene vicleucel (ide-cel; n = 266) or ciltacabtagene autoleucel (cilta-cel; n = 77) after >3 previous lines of therapy in Germany. Cilta-cel, compared with ide-cel, demonstrated superior outcomes, achieving a higher overall response rate (94% vs 82%) and 10-month progression-free survival (PFS; 76% vs 47%). Cilta-cel also led to higher complete response (CR; 61% vs 39%) and improved response conversion, with more patients achieving CR after starting from less than CR before chimeric antigen receptor T-cell (CAR T) therapy. For those attaining CR after therapy, cilta-cel showed longer PFS, especially in patients who entered treatment with a partial response or worse. Cytokine release syndrome was observed in 85% of cilta-cel and 81% of ide-cel cases, predominantly low grade. Immune effector cell–associated neurotoxicity syndrome was more common with cilta-cel (25% vs 15%), although nonrelapse mortality at 10 months was comparable between therapies (7% vs 5%). Weighted multivariable analysis after propensity score matching confirmed a significant advantage in terms of PFS for cilta-cel, with a hazard ratio of 0.48. Overall, outcomes in our registry analysis were comparable with the pivotal trials that led to approval of the respective agents. Cilta-cel demonstrated a greater capacity for response conversion and durable remission. These findings underscore the need for individualized CAR T therapy selection to optimize patient outcomes.

3 August 2024 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
NGNico Gagelmann
Nico Gagelmann
CSClaudia Schuh
Claudia Schuh
RZRobert Zeiser
Robert Zeiser
MSMatthias Stelljes
Matthias Stelljes
WBWolfgang Bethge
Wolfgang Bethge
Nicolaus KrögerNicolaus Kröger
Nicolaus Kröger

5 December 2024 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
NGNora Grieb
Nora Grieb
AOAlexander Oeser
Alexander Oeser
MFMaximilian Ferle
Maximilian Ferle
FHFranziska Hanke
Franziska Hanke
SFSarah Flossdorf
Sarah Flossdorf
O(On Behalf Of The German Registry For Hematopoietic Stem Cell Transplantation And Cell Therapy (Drst)
On Behalf Of The German Registry For Hematopoietic Stem Cell Transplantation And Cell Therapy (Drst)
Identifying patients who may benefit from autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma is crucial, especially in the era of effective induction and consolidation strategies. We analyzed data from 12763 patients enrolled in the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST), distinguishing those who underwent single (n = 8736) or tandem ASCT (n = 4027) from 1998 to 2021. Our findings show that the median age at first ASCT increased over time, while the use of tandem ASCT declined. The shift in treatment practices coincided with higher rates of complete response (CR) post-induction therapy. Significantly improved overall survival and event-free survival over time were observed across all age groups, especially in older patients, but not in patients under 40. Tandem ASCT showed benefits for patients who did not achieve CR after initial ASCT. However, patients with ISS III and renal impairment had poorer outcomes with tandem ASCT. In conclusion, while ASCT remains an important anti-myeloma tool, careful patient selection for tandem ASCT is essential, particularly avoiding its use in patients with ISS III and renal impairment, older age, and those already achieving CR after initial ASCT.

8 April 2025 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
CRChristina Rautenberg
Christina Rautenberg
JMJan Moritz Middeke
Jan Moritz Middeke
CRChristoph Röllig
Christoph Röllig
MSMatthias Stelljes
Matthias Stelljes
VGVerena Gaidzik
Verena Gaidzik
FSFriedrich Stölzel
Friedrich Stölzel
Real-world experience with first

27 December 2022 in British Journal of Haematology
Verified
Journal Article
Open access
JFJochen Frietsch
Jochen Frietsch
SFSarah Flossdorf
Sarah Flossdorf
JBJames F. Beck
James F. Beck
Nicolaus KrögerNicolaus Kröger
Nicolaus Kröger
KFKatharina Fleischhauer
Katharina Fleischhauer
IHInken Hilgendorf
Inken Hilgendorf
Summary: Young adults (YA) represent a minority among recipients of allogeneic haematopoietic stem cell transplantation (HSCT). In order to describe the outcome of YA following HSCT in Germany, 9299 patients who were registered with the German Registry for Stem Cell Transplantation were included in this retrospective analysis of the years 1998–2019. The impact of the variables, such as patient age and sex, sex differences, stem cell source, donor type, conditioning, year of HSCT, the diagnosis, and the achieved remission status were tested in univariable and multivariable analysis for overall, event‐free and relapse‐free survival as well as for the cumulative incidences of non‐relapse and therapy‐related mortality. Altogether, the outcome of YA after HSCT improved over time and was determined by the underlying disease, the age at disease onset, stem cell source, and donor type. Patients were most likely to die from relapse, and survival of HSCT recipients after 10 years was reduced by more than half in comparison to the general population of YA. Deeper understanding of modifiable risk factors may be gained by studies comparing the outcome of YA post‐HSCT with that of children, adolescents and elderly patients. A deliberate and strong patient selection may further improve mortality rates.

12 August 2025 in Transfusionsmedizin
Verified
Journal Article
Closed access
PDF file
NKNicolaus Kröger
Nicolaus Kröger
FHFranziska Hanke
Franziska Hanke
HNHelga Neidlinger
Helga Neidlinger
SSSamih Smaili
Samih Smaili
SMSophie Mannes
Sophie Mannes
KFKatharina Fleischhauer
Katharina Fleischhauer
Zusammenfassung: Das Deutsche Register für hämatopoetische Stammzelltransplantation und Zelltherapie (DRST) führt die Registrierung der klinischen Aktivität der autologen und allogenen Blutstammzelltransplantation sowie der zellulären Therapien in Deutschland datenschutzrechtlich konform und in dokumentierter trilateraler Übereinkunft mit den klinischen Zentren und der European Society for Blood and Marrow Transplantation (EBMT) durch. Aktuell sind über 88 000 autologe und fast 70 000 allogene Stammzelltransplantationen sowie mehr als 3600 chimeric antigen receptor T-Zell-Therapien (CAR-T) im DRST verzeichnet. Aus den über 25 Jahren dieser Aufzeichnungen ergibt sich in den letzten Jahren ein leichter Rückgang der autologen Stammzelltransplantationen, vermutlich aufgrund alternativer Therapieformen. Hingegen lässt sich bei den allogenen Stammzelltransplantationen weiterhin ein Anstieg verzeichnen, was auf einen starken Anstieg des Alters der Patienten, denen diese Therapiemöglichkeit angeboten werden kann, sowie auf eine Anpassung der Indikationsstellung hin zu akuten Leukämien und myeloischen Neoplasien zurückzuführen ist. Die CAR-T-Aktivität ist vor allem für das multiple Myelom angestiegen, und es ist zu erwarten, dass dieser Trend sich mit Einschluss weiterer Entitäten wie den Autoimmunerkrankungen weiter fortsetzt. Durch das DRST werden zudem retrospektive Studien zu spezifischen Fragestellungen ermöglicht, was seine wichtige Rolle für medizinische, wissenschaftliche und gesundheitspolitische Fragen unterstreicht.